Institute for Quality and Efficiency in Health Care

Afatinib: Added benefit depends on mutation status

Afatinib (trade name: GIOTRIF) has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations ...

Feb 19, 2014
popularity not rated yet | comments 0

Regorafenib: Hint of minor added benefit

Regorafenib (trade name: Stivarga) has been approved in Germany since August 2013 for adults with metastatic colorectal cancer in whom previous treatments are no longer effective or for whom these alternatives are not an ...

Jan 10, 2014
popularity not rated yet | comments 0

COPD: DMP is largely consistent with guidelines

On 3 January 2014 the German Institute for Quality and Efficiency in Health Care (IQWiG) published the results of a literature search for evidence-based clinical practice guidelines on the treatment of people with chronic ...

Jan 08, 2014
popularity not rated yet | comments 0

Dabrafenib in melanoma: Added benefit not proven

Dabrafenib (trade name: Tafinlar) has been approved in Germany since August 2013 for the treatment of advanced melanoma.In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products ...

Jan 07, 2014
popularity not rated yet | comments 0

Aflibercept in macular oedema: Added benefit not proven

For the third time in one year, the German Institute for Quality and Efficiency in Health Care (IQWiG) dealt with the drug aflibercept. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal ...

Jan 07, 2014
popularity not rated yet | comments 0

Vemurafenib: Result unchanged despite new data

Pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed vemurafenib (trade name: Zelboraf), a drug for the treatment ...

Dec 18, 2013
popularity not rated yet | comments 0

Enzalutamide in prostate cancer: Hints of added benefit

Enzalutamide (trade name: Xtandi) has been approved since June 2013 for men with metastatic prostate cancer in whom the commonly used hormone blockade is no longer effective and who have already been treated with the cytostatic ...

Dec 06, 2013
popularity not rated yet | comments 0